대사성 산증 치료를 위한 Veverimer의 효능 및 안전성 평가 연구
만성 신장 질환 및 대사성 산증이 있는 성인에서 Veverimer의 유효성 및 안전성을 평가하기 위한 제3상, 무작위, 이중 맹검 연구 (REVIVE 연구)
The purpose of this study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Ayla Rasmussen
- 전화번호: 443-569-9228
- 이메일: arasmussen@renibus.com
연구 장소
-
-
California
-
Chula Vista, California, 미국, 91910
- 모병
- Study Site
-
Los Angeles, California, 미국, 90022
- 모병
- Study Site
-
Sacramento, California, 미국, 95817
- 모병
- Study Site
-
San Diego, California, 미국, 92111
- 모병
- Study Site
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Study Site
-
-
Delaware
-
Newark, Delaware, 미국, 19713
- 모병
- Study Site
-
-
Florida
-
Edgewater, Florida, 미국, 32132
- 모병
- Study Site
-
Margate, Florida, 미국, 33063
- 모병
- Study Site
-
Miami Springs, Florida, 미국, 33166
- 모병
- Study Site
-
Orlando, Florida, 미국, 32806
- 모병
- Study Site
-
-
Georgia
-
Augusta, Georgia, 미국, 30904
- 종료됨
- Study Site
-
-
Idaho
-
Boise, Idaho, 미국, 83706
- 모병
- Study Site
-
Chubbuck, Idaho, 미국, 83201
- 모병
- Study Site
-
Idaho Falls, Idaho, 미국, 83401
- 모병
- Study Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60643
- 모병
- Study Site
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Study Site
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40205
- 모병
- Study Site
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- 모병
- Study Site
-
-
Michigan
-
Detroit, Michigan, 미국, 48202
- 모병
- Study Site
-
Pontiac, Michigan, 미국, 48341
- 모병
- Study Site
-
-
Missouri
-
Kansas City, Missouri, 미국, 64111
- 모병
- Study Site
-
-
New York
-
Fresh Meadows, New York, 미국, 11365
- 모병
- Study Site
-
New York, New York, 미국, 10016
- 모병
- Study Site
-
-
North Carolina
-
Winston-Salem, North Carolina, 미국, 27103
- 모병
- Study Site
-
-
Texas
-
Fort Worth, Texas, 미국, 76110
- 모병
- Study Site
-
Houston, Texas, 미국, 77054
- 모병
- Study Site
-
San Antonio, Texas, 미국, 78212
- 모병
- Study Site
-
Van Vleck, Texas, 미국, 77482
- 모병
- Study Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Have provided written informed consent prior to participation in the study.
- Male or female participants 18 years of age or older.
- Diagnosed with CKD (eGFR < 60 mL/min/1.73m2) and not expected to require renal replacement therapy (dialysis or kidney transplant) throughout the duration of the study.
- Within 6 months prior to screening have at least two SBC between 12 and 20 mmol/L, inclusive. If only one historical SBC is available, a second SBC may be drawn on screening visit S1 and analyzed by the local laboratory.
- Within screening period have two central laboratory SBC (at least 24 hours apart and more than 4 hours after food) between 12 and 21 mmol/L, inclusive.
- Willing to keep food consumption similar to baseline throughout the entire study.
- If taking oral alkali therapy, dose has been stable for at least 28 days prior to the start of screening and is expected to remain stable throughout the study.
- Women who are of childbearing potential must have a negative pregnancy test and agree to abstinence or to use contraception.
Exclusion Criteria:
-
Any participant deemed by the Investigator to be an inappropriate candidate for PerfO testing (e.g., severe musculoskeletal pain, non-ambulatory status), inability to complete STS5 without support or with a screening STS5 time < 10 seconds.
-
History or current diagnosis of:
- Clinically significant gastroparesis or a history of bariatric surgery.
- Bowel obstruction, swallowing disorders, severe gastrointestinal disorders, including inflammatory bowel disease, major gastrointestinal surgery including gastrectomy, or known active gastric/duodenal ulcers.
- Severe recurrent diarrhea or constipation, as assessed by the Investigator.
- Pernicious anemia, atrophic or autoimmune gastritis, achlorhydria or hypochlorhydria.
-
Ineligible per REVIVE GastroScreen test.
-
Use of GI polymer binders or sodium zirconium cyclosilicate within 14 days prior to the start of screening or have an expectation to initiate treatment during the study.
-
Use of acid reducing drugs, including PPIs, H2RAs or P-CABs within 14 days prior to the start of screening or have an expectation to initiate treatment during the study. Very sporadic use (one time per week or less) may be acceptable, as assessed by the Investigator.
-
Initiation of GLP-1 receptor agonists within 6 months prior to the start of screening, or expectation to initiate use during the study. Participants that have been on a GLP-1 receptor agonist for more than 6 months and have maintained a stable dose and steady body weight for at least one month prior to the start of screening may be considered for enrollment, upon Medical Monitor review. GLP-1 receptor agonists also should not be started during the study.
-
Participants that are taking any of the following medications and have not been on a stable dose for at least 14 days prior to the start of screening or have an expectation to change dose during the study: diuretics, non-ophthalmic carbonic anhydrase inhibitors, diabetes drugs, RAAS inhibitors, calcium or magnesium supplements, non-polymer phosphate binders, and SGLT-2 inhibitors. These medications also should not be started during the study.
-
Active, recurrent, or metastatic malignancy at the start of screening.
-
History of malignancy, except under the following conditions:
- Carcinoma in situ (e.g., of the cervix, breast, or bladder) that has been completely excised and shows no evidence of residual disease.
- Non-melanoma skin cancers (e.g., basal cell carcinoma, squamous cell carcinoma) that have been completely excised and show no evidence of recurrence.
- Low grade prostate cancer, in the opinion of the Investigator (i.e., no metastasis, Gleason score < 6), with no significant worsening for > 6 months prior to the screening visit.
- Any other malignancy that was treated with curative intent and has been in complete remission for ≥ 5 years prior to the screening visit.
-
Two or more hospitalizations within 12 months prior to the start of screening or a hospitalization within the last 3 months prior to the start of screening due to fluid overload, heart failure, acute kidney injury (AKI) or electrolyte disorders, including hyperkalemia. Participants that have not been hospitalized within the past 3 months and whose condition is stable may be considered for enrollment.
-
Screening hemoglobin < 9 g/dL.
-
Low bicarbonate value(s) at time of screening that are due to underlying primary respiratory alkalosis.
-
Investigational medication administration within 28 days prior to start of screening.
-
Participants that are taking an average of > 30 units of insulin daily, unless recent (within last 6 months) hemoglobin A1C is < 6.5%.
-
History of alcoholism or drug/chemical abuse within 1 year prior to the start of screening, in the opinion of the Investigator.
-
Current, regular use of inhaled/ingested cannabis/THC products.
-
Inability to take the IP or otherwise comply with the protocol.
-
Any medical condition, uncontrolled systemic disease or serious concurrent illness that would significantly decrease study compliance or jeopardize the safety of the participant or affect the validity of the trial results, in the opinion of the Investigator.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: 위약
|
Group 2: 9 g PBO BID |
|
실험적: 베베리머
|
Group 1: 9 g veverimer BID |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
혈청 중탄산염 농도(SBC) 변화 측정을 통한 베베리머의 효능
기간: 방문: 선별 검사부터 168일차까지
|
방문: 선별 검사부터 168일차까지
|
|
Veverimer의 효과는 5회 앉았다 일어서기 검사(STS5)를 통해 평가된 신체 기능 개선에서 나타납니다.
기간: 방문: 스크리닝부터 168일차까지
|
방문: 스크리닝부터 168일차까지
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].
기간: Visits: Screening to Day 168
|
Visits: Screening to Day 168
|
|
|
Efficacy of Veverimer in achieving SBC and responder thresholds.
기간: Visits: Screening to Day 168
|
Change from baseline in SBC. Achievement of SBC thresholds (> 4 mmol/L increase from baseline and/or > 23 mmol/L). |
Visits: Screening to Day 168
|
|
Performance outcomes (PerfO).
기간: Visits: Screening to Day 168
|
Change in Patient Global Impression of Change of Physical Functioning (PGI-C) Patients answer 1 question: How would you rate your current level of physical functioning (mobility and ability to do everyday physical activities) compared to the beginning of the study? Much better, Moderately better, A little better, No change, A little worse, Moderately worse, Much worse. Lower score is a better outcome. Change in Patient Global Impressions Scale - Severity (PGI-S) Patients answer 1 question: How would you rate your current level of physical functioning (mobility and ability to do everyday physical activities)? Poor, Fair, Good, Very good, Excellent. Higher score is a better outcome. |
Visits: Screening to Day 168
|
|
Frailty and muscle mass assessment.
기간: Visits: Screening to Day 168
|
Change in performance on 6-minute walk test 6MWT. |
Visits: Screening to Day 168
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .